Injective’s 12% slide this month has left traders questioning whether the downturn is just temporary turbulence or a signal of deeper weakness. With Q4 in motion, attention is on whether INJ can muster enough strength to reclaim higher ground and potentially retest the $20 level. This analysis looks at Injective’s current technical setup and what factors could drive its next decisive move. Injective (INJ) Displays Mixed Signals Amid Price Struggles Source: tradingview  Injective (INJ) is navigating choppy waters with its current price between nearly $14 and $17. The coin faces a tough ceiling at $18, while finding some ground just above $12. Lately, the price has dipped by more than 10% in a week, showing a weakening trend over the month and the past six months as well. Despite the current downturn, if market conditions improve, there is potential for growth. INJ could surge over 25% to the next major resistance at $21. However, with an RSI of 38, the coin is not oversold yet, leaving plenty of room for potential upward momentum if the bulls take charge. Conclusion Despite recent declines, Injective’s support near $12 and resistance around $18–$21 provide a clear roadmap for potential recovery. With its RSI still leaving room for upward momentum, a rebound toward $20 remains on the table if buying pressure picks up. While caution is warranted given recent weakness, INJ could still surprise with a late-year push, making it one to watch closely through Q4. Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.Injective’s 12% slide this month has left traders questioning whether the downturn is just temporary turbulence or a signal of deeper weakness. With Q4 in motion, attention is on whether INJ can muster enough strength to reclaim higher ground and potentially retest the $20 level. This analysis looks at Injective’s current technical setup and what factors could drive its next decisive move. Injective (INJ) Displays Mixed Signals Amid Price Struggles Source: tradingview  Injective (INJ) is navigating choppy waters with its current price between nearly $14 and $17. The coin faces a tough ceiling at $18, while finding some ground just above $12. Lately, the price has dipped by more than 10% in a week, showing a weakening trend over the month and the past six months as well. Despite the current downturn, if market conditions improve, there is potential for growth. INJ could surge over 25% to the next major resistance at $21. However, with an RSI of 38, the coin is not oversold yet, leaving plenty of room for potential upward momentum if the bulls take charge. Conclusion Despite recent declines, Injective’s support near $12 and resistance around $18–$21 provide a clear roadmap for potential recovery. With its RSI still leaving room for upward momentum, a rebound toward $20 remains on the table if buying pressure picks up. While caution is warranted given recent weakness, INJ could still surprise with a late-year push, making it one to watch closely through Q4. Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Injective Slides 12% This Month – Will INJ Bounce Back Toward $20 in Q4?

Injective’s 12% slide this month has left traders questioning whether the downturn is just temporary turbulence or a signal of deeper weakness. With Q4 in motion, attention is on whether INJ can muster enough strength to reclaim higher ground and potentially retest the $20 level. This analysis looks at Injective’s current technical setup and what factors could drive its next decisive move.

Injective (INJ) Displays Mixed Signals Amid Price Struggles

Source: tradingview 

Injective (INJ) is navigating choppy waters with its current price between nearly $14 and $17. The coin faces a tough ceiling at $18, while finding some ground just above $12. Lately, the price has dipped by more than 10% in a week, showing a weakening trend over the month and the past six months as well. Despite the current downturn, if market conditions improve, there is potential for growth. INJ could surge over 25% to the next major resistance at $21. However, with an RSI of 38, the coin is not oversold yet, leaving plenty of room for potential upward momentum if the bulls take charge.

Conclusion

Despite recent declines, Injective’s support near $12 and resistance around $18–$21 provide a clear roadmap for potential recovery. With its RSI still leaving room for upward momentum, a rebound toward $20 remains on the table if buying pressure picks up. While caution is warranted given recent weakness, INJ could still surprise with a late-year push, making it one to watch closely through Q4.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.885
$1.885$1.885
+4.02%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

XRP Delivers Impressive ETF Volumes But Digitap ($TAP) is the King of Cross-Border Payments in 2026

XRP Delivers Impressive ETF Volumes But Digitap ($TAP) is the King of Cross-Border Payments in 2026

XRP has dominated crypto headlines recently. Spot XRP ETFs brought over $1 billion in institutional inflows, and total ETF-held assets now sit at $1.47 billion.
Share
Brave Newcoin2026/01/14 03:58
Strive Completes Acquisition of Bitcoin Treasury Firm Semler

Strive Completes Acquisition of Bitcoin Treasury Firm Semler

The post Strive Completes Acquisition of Bitcoin Treasury Firm Semler appeared on BitcoinEthereumNews.com. Strive Inc. (ASST) and Semler scientific (SMLR) were
Share
BitcoinEthereumNews2026/01/14 04:29
Wormhole token soars following tokenomics overhaul, W reserve launch

Wormhole token soars following tokenomics overhaul, W reserve launch

                                                                               Wormhole’s native token has had a tough time since launch, debuting at $1.66 before dropping significantly despite the general crypto market’s bull cycle.                     Wormhole, an interoperability protocol facilitating asset transfers between blockchains, announced updated tokenomics to its native Wormhole (W) token, including a token reserve and more yield for stakers. The changes could affect the protocol’s governance, as staked Wormhole tokens allocate voting power to delegates.According to a Wednesday announcement, three main changes are coming to the Wormhole token: a W reserve funded with protocol fees and revenue, a 4% base yield for staking with higher rewards for active ecosystem participants, and a change from bulk unlocks to biweekly unlocks.“The goal of Wormhole Contributors is to significantly expand the asset transfer and messaging volume that Wormhole facilitates over the next 1-2 years,” the protocol said. According to Wormhole, more tokens will be locked as adoption takes place and revenue filters back to the company.Read more
Share
Coinstats2025/09/18 02:41